About this poster
Glioblastoma remains one of the most aggressive brain tumors, with dismal clinical outcomes. A challenge made all the more daunting by the inadequacy of conventional 2D and animal models to recapitulate the structural and cellular complexity of the human tumor microenvironment. IRBM’s C3PO (Complex 3D Patient Organoids) platform addresses this gap by integrating patient-derived glioma stem-like cells with astrocytes and microglia into self-assembled, multicellular spheroids that reproduce key TME features — including nutrient and oxygen gradients, cell-ECM interactions, and subtype-specific genomic profiles. Tested across multiple GBM subtypes and compounds, C3POs reveal resistance mechanisms hidden in 2D assays and yield potency values that correlate more closely with in vivo efficacy data, supporting stronger translational confidence in compound prioritization. Download the poster to explore the full model characterization, drug-response data, and in vitro–in vivo comparisons in detail.
Get the full poster
Free PDF, sent to your work email.
C3PO GBM 3D Organoid DrugTesting poster, code 26006